Journal of Clinical and Translational Endocrinology最新文献

{"title":"Development and acceptability of a culturally competent skills and knowledge assessment tool for patients with diabetes mellitus","authors":"Stephanie Hakimian ,&nbsp;Susan Karam ,&nbsp;Kim Pardilla ,&nbsp;Kasey Coyne ,&nbsp;Emilie K. Touma ,&nbsp;Diane Larsen ,&nbsp;Jane L. Holl ,&nbsp;Amisha Wallia","doi":"10.1016/j.jcte.2024.100346","DOIUrl":"10.1016/j.jcte.2024.100346","url":null,"abstract":"<div><h3>Background</h3><p>Patients newly diagnosed with type 2 diabetes mellitus (DM) and newly prescribed insulin need to learn essential self-care and management skills quickly. To optimize teaching, clinicians need to assess a patient’s basic understanding of DM and their skills. While DM patient assessments exist, this study reports the development of an assessment of patient DM management skills and knowledge, using feedback from DM clinicians, patients, and caregivers.</p></div><div><h3>Research Design and Methods</h3><p>A systematic search of Pubmed/Medline and Scopus (1980–2017) of DM knowledge assessments was performed. Twenty-four studies were identified. Content from the existing assessments was adapted to create a 12 item DM-Skills Knowledge Assessment (SKA) to assess a patient’s DM management skills and knowledge. To assess cultural humility, modified cognitive interviews were conducted in individual user sessions and semi-structured focus groups. Audio-transcripts of the interviews/focus groups were independently coded, and codes were grouped into key themes. Participant demographic characteristics were assessed.</p></div><div><h3>Results</h3><p>Five focus groups and eleven key informant interviews were conducted, including 10 DM clinicians, 12 patients/caregivers, and 15 laypersons. All 10 clinicians reported that the DM-SKA addresses the key domains of DM education deemed to be of highest importance during the transition from hospital to home and that their patients would be willing to complete the assessment. More than half of the patient/caregiver/layperson participants self-reported race/ethnicity other than non-Hispanic white and performed similarly to non-Hispanic white participants in understanding each item, willingness to complete the DM-SKA, and perception that family or community members would be willing to complete the DM-SKA. The DM-SKA has a baseline Flesch reading score of 81.3, indicating low complexity language.</p></div><div><h3>Conclusion</h3><p>DM clinicians agreed that the DM-SKA assesses all essential DM management skills. For patients/caregivers, it has acceptable literacy, cognitive validity, and culturally acceptable for racial/ethnic minority populations in the study, including elderly persons.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100346"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000176/pdfft?md5=d39e54ecec04fe73442e0286ba3b827b&pid=1-s2.0-S2214623724000176-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140764251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial inequities and rare CFTR variants: Impact on cystic fibrosis diagnosis and treatment","authors":"Malinda Wu ,&nbsp;Jacob D. Davis ,&nbsp;Conan Zhao ,&nbsp;Tanicia Daley ,&nbsp;Kathryn E. Oliver","doi":"10.1016/j.jcte.2024.100344","DOIUrl":"10.1016/j.jcte.2024.100344","url":null,"abstract":"<div><p>Cystic fibrosis (CF) has been traditionally viewed as a disease that affects White individuals. However, CF occurs among all races, ethnicities, and geographic ancestries. The disorder results from mutations in the <em>CF transmembrane conductance regulator</em> (<em>CFTR</em>). Varying incidence of CF is reported among Black, Indigenous, and People of Color (BIPOC), who typically exhibit worse clinical outcomes. These populations are more likely to carry rare <em>CFTR</em> variants omitted from newborn screening panels, leading to disparities in care such as delayed diagnosis and treatment. In this study, we present a case-in-point describing an individual of Gambian descent identified with CF. Patient genotype includes a premature termination codon (PTC) (c.2353C&gt;T) and previously undescribed single nucleotide deletion (c.1970delG), arguing against effectiveness of currently available CFTR modulator-based interventions. Strategies for overcoming these two variants will likely include combinations of PTC suppressors, nonsense mediated decay inhibitors, and/or alternative approaches (e.g. gene therapy). Investigations such as the present study establish a foundation from which therapeutic treatments may be developed. Importantly, c.2353C&gt;T and c.1970delG were not detected in the patient by traditional <em>CFTR</em> screening panels, which include an implicit racial and ethnic diagnostic bias as these tests are comprised of mutations largely observed in people of European ancestry. We suggest that next-generation sequencing of <em>CFTR</em> should be utilized to confirm or exclude a CF diagnosis, in order to equitably serve BIPOC individuals. Additional epidemiologic data, basic science investigations, and translational work are imperative for improving understanding of disease prevalence and progression, <em>CFTR</em> variant frequency, genotype-phenotype correlation, pharmacologic responsiveness, and personalized medicine approaches for patients with African ancestry and other historically understudied geographic lineages.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100344"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000152/pdfft?md5=5090e775b1523be2a90facba1ac9ddce&pid=1-s2.0-S2214623724000152-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140775798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Family planning preferences in transgender youth in an urban multi-disciplinary gender clinic","authors":"Ryan Conard ,&nbsp;Lisal Folsom","doi":"10.1016/j.jcte.2024.100353","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100353","url":null,"abstract":"<div><h3>Background</h3><p>Known barriers to family planning in the transgender population include low utilization of cryopreservation and decisional regret. There is growing data on the risk of infertility with GAHT, and on to what degree transgender adolescents feel informed about fertility and family planning options.</p></div><div><h3>Objective</h3><p>Assess preferences regarding options for family planning and fertility preservation in transgender adolescents treated with GAHT in a pediatric endocrinology gender clinic. The goal is to enhance patient education about potential effects of GAHT on fertility and options for family planning.</p></div><div><h3>Methods</h3><p>Forty one adolescents aged 10 years and older treated with GAHT in an urban outpatient pediatric endocrinology clinic were surveyed over a 6-month period from January to June 2022. Survey questions were multiple choice, Likert scale, and open-ended. Participants were at least 10 years of age, actively followed in the clinic, and receiving GAHT at time of enrollment.</p></div><div><h3>Results</h3><p>Forty one participants completed the survey. Four (10 %) expressed interest in discussing family planning with their provider. Eighteen (45 %) were open to discussion in the future; 16 (39 %) were not interested at all. 12 (30 %) participants were planning for future parenthood, and 16 (40 %) participants were undecided. Of those interested in parenthood 7 (53.8 %) planned to adopt or foster. Barriers to family planning expressed included financial concerns, potential need to pause GAHT, and social stigma of transgender parenthood. Twenty (50 %) participants recalled prior family planning discussion with their endocrinologist.</p></div><div><h3>Conclusion</h3><p>Family planning discussions may not be optimally impactful given that 50 % of participants did not recall the conversations. Family planning is a lower priority in this population as most desired to postpone discussion with their provider despite choosing treatment that could influence fertility. It is essential to identify methods to engage transgender youth in discussions related to family planning during GAHT.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100353"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000243/pdfft?md5=64aa9a33c2b6dd2804b28bf27528fa9e&pid=1-s2.0-S2214623724000243-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141091064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insulin sensitivity, body composition and bone mineral density after testosterone treatment in transgender youth with and without prior GnRH agonist therapy","authors":"Natalie J. Nokoff ,&nbsp;Samantha Bothwell ,&nbsp;John D. Rice ,&nbsp;Melanie G. Cree ,&nbsp;Megan M. Kelsey ,&nbsp;Kerrie L. Moreau ,&nbsp;Philip Zeitler ,&nbsp;Kristen J. Nadeau","doi":"10.1016/j.jcte.2024.100356","DOIUrl":"10.1016/j.jcte.2024.100356","url":null,"abstract":"<div><h3>Background</h3><p>1.8% of youth identify as transgender; a growing proportion are transgender male (female sex, male gender identity). Many receive gonadotropin releasing hormone agonist (GnRHa) therapy to suppress endogenous puberty and/or will start testosterone to induce secondary sex characteristics that align with gender identity.</p></div><div><h3>Objective(s)</h3><p>To determine the effects of 12 months of testosterone on cardiometabolic health among transgender youth, including insulin sensitivity, body composition, and bone mineral density and whether changes in outcomes differ based on prior GnRHa treatment.</p></div><div><h3>Methods</h3><p>Participants (n = 19, baseline age 15.0 ± 1.0 years) were examined prior to and 12 months after testosterone therapy in a longitudinal observational study. Fasted morning blood draw, a 2-hour 75-gram oral glucose tolerance test, body composition and bone mineral density (dual-energy X-ray absorptiometry) were assessed at baseline and 12 months. Insulin sensitivity was estimated by HOMA-IR and Matsuda index. Changes were compared with mixed linear regression models evaluating time (baseline, 12 months), group (GnRHa treatment yes/no), and their interaction.</p></div><div><h3>Results</h3><p>In the entire cohort, fasted insulin decreased (median [25,75 %ile]: −3 [-5, 0] mIU/L, p = 0.044) and 2-hour glucose increased (mean ± standard deviation): +18.5 ± 28.9 mg/dL, p = 0.013 from baseline after 12 months of testosterone therapy. There were no significant changes in HOMA-IR (p = 0.062) or Matsuda index (p = 0.096), nor by GnRHa status. Absolute (+6.2 [4.7, 7.5] kg, p = 0.016) and percent fat-free mass increased (+7.3 [5.4, 9.1] %, p = 0.003) and percent fat mass declined (−7.4 [-9.3, 5.3]%, p = 0.005) for the entire cohort. There were time*group interactions for absolute (p = 0.0007) and percent fat-free mass (p = 0.033). There were time*group interactions for bone mineral content (p = 0.006).</p></div><div><h3>Conclusions</h3><p>Twelve months of testosterone in transgender adolescents resulted in changes in body composition and bone mineral density, with baseline differences between the +/-GnRHa group and convergence after 12 months. There were no changes in insulin sensitivity over time or between groups.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100356"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000279/pdfft?md5=2666e91ba02defc0ebabb88a0dd45cf2&pid=1-s2.0-S2214623724000279-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141232855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olfactory function in diabetes mellitus","authors":"Beata Sienkiewicz-Oleszkiewicz ,&nbsp;Thomas Hummel","doi":"10.1016/j.jcte.2024.100342","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100342","url":null,"abstract":"<div><p>Diabetes mellitus (DM) is an increasingly common disease in both children and adults. In addition to neuronal and/or vascular disorders, it can cause chemosensory abnormalities including olfactory deterioration. The purpose of this article is to summarize current knowledge on olfactory function in DM, highlighting the impact of co-morbidities, especially obesity, thyroid dysfunction, chronic kidney disease and COVID-19 on olfactory outcomes. Research to date mostly shows that olfactory impairment is more common in people with diabetes than in the general population. In addition, the presence of concomitant diseases is a factor increasing olfactory impairment. Such a correlation was shown for type 1 diabetes, type 2 diabetes and gestational diabetes. At the same time, not only chronic diseases, but also DM in acute conditions such as COVID-19 leads to a higher prevalence of olfactory disorders during infection. Analyzing the existing literature, it is important to be aware of the limitations of published studies. These include the small number of patients studied, the lack of uniformity in the methods used to assess the sense of smell, frequently relying on rated olfactory function only, and the simultaneous analysis of patients with different types of diabetes, often without a clear indication of diabetes type. In addition, the number of available publications is small. Certainly, further research in this area is needed. From a practical point of view decreased olfactory performance may be an indicator for central neuropathy and an indication for assessing the patient's nutritional status, examining cognitive function, especially in older patients and performing additional diagnostic tests, such as checking thyroid function, because all those changes were correlated with smell deterioration.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100342"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000139/pdfft?md5=dd014507ee998a4d38dcf5c11f389f78&pid=1-s2.0-S2214623724000139-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140345352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maximizing surgical outcomes with gender affirming hormone therapy in gender affirmation surgery","authors":"Desha Gelles-Soto ,&nbsp;Danielle Ward ,&nbsp;Taylor Florio ,&nbsp;Konstantinos Kouzounis ,&nbsp;Christopher J. Salgado","doi":"10.1016/j.jcte.2024.100355","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100355","url":null,"abstract":"<div><p>Gender Affirmation Surgery (GAS) is a super specialized subset within the field of plastic and reconstructive surgery (PRS) that is ever evolving and of increasing interest to the PRS community. It is a multifaceted process which, in addition to surgical therapy, involves mental health therapy and hormonal therapy. One rapidly emerging interest within GAS is the role that gender affirming hormone therapy (GAHT) plays in enhancing surgical outcomes. GAHT has been used adjunctively with GAS as a comprehensive therapy to ameliorate gender dysphoria. This literature review will examine the positive effects of GAHT on the surgical outcomes on GAS, as well as other important considerations prior to surgery. As such, the primary objective of this literature review is to evaluate and assess the current evidence concerning the efficacy and safety of GAHT, as it relates to Gender Affirmation Surgery procedures.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100355"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000267/pdfft?md5=a2ccc9a180e1d6e22273188733ad8f53&pid=1-s2.0-S2214623724000267-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141243127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or Post-Transplant diabetes","authors":"Moeber Mohammed Mahzari ,&nbsp;Omar Buraykan Alluhayyan ,&nbsp;Mahdi Hamad Almutairi ,&nbsp;Mohammed Abdullah Bayounis ,&nbsp;Yazeed Hasan Alrayani ,&nbsp;Amir A. Omair ,&nbsp;Awad Saad Alshahrani","doi":"10.1016/j.jcte.2024.100343","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100343","url":null,"abstract":"<div><h3>Objective</h3><p>Type 2 diabetes mellitus (T2DM) and post-transplant diabetes mellitus (PTDM) are common in renal transplant recipients. Semaglutide has demonstrated efficacy and safety in patients with T2DM. To date, only a limited number of studies have investigated its use in renal transplant patients. This study assessed the safety and efficacy of semaglutide in post-renal transplant patients.</p></div><div><h3>Methods</h3><p>A retrospective study was conducted at king Abdulaziz Medical City-Riyadh, Saudi Arabia. The subjects of the study were adults and adolescents (&gt;14 years) who had undergone a kidney transplant and had pre-existing T2DM or PTDM. The study subjects were given semaglutide during the study period, from January 2018 to July 2022. The data were collected over a period of 18 months.</p></div><div><h3>Results</h3><p>A total of 39 patients were included, 29 (74 %) of whom were male. A significant decrease in hemoglobin A1c (HbA1c) was observed during the follow-up period when compared to baseline (8.4 %±1.3 % at baseline vs. 7.4 %±1.0 % at 13–18 months (p &lt; 0.001). A significant reduction in weight was also noted at follow-up as compared to baseline (99.5 kg ± 17.7 vs 90.7 kg ± 16.8 at 13–18 months (p &lt; 0.001). No significant changes were found in renal graft function markers.</p></div><div><h3>Conclusion</h3><p>Semaglutide was found to significantly reduce HbA1c levels and weight in post renal transplant patients with diabetes. No significant changes in markers of renal graft function were observed.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100343"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000140/pdfft?md5=347e3e769ad4860c814d5d6d05fc57b6&pid=1-s2.0-S2214623724000140-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140536961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histopathology of telomerase reverse transcriptase promoter (TERT) mutated indeterminate thyroid nodules","authors":"Jessica O. Pinto ,&nbsp;Masha J. Livhits ,&nbsp;Michael W. Yeh ,&nbsp;Atanas Kaykov ,&nbsp;Joshua P. Klopper ,&nbsp;Richard T. Kloos ,&nbsp;Mohammed Alshalalfa ,&nbsp;Yangyang Hao ,&nbsp;Jing Huang ,&nbsp;Mayumi Endo","doi":"10.1016/j.jcte.2023.100329","DOIUrl":"10.1016/j.jcte.2023.100329","url":null,"abstract":"<div><h3>Objective</h3><p>The objective of this study was to analyze the risk of malignancy and the histopathology of telomerase reverse transcriptase promoter <em>(TERT)</em> mutated cytologically indeterminate thyroid nodules (ITN).</p></div><div><h3>Methods</h3><p>A PUBMED search of molecularly tested ITN was conducted and data on <em>TERT</em> mutated ITN with histopathology correlation were extracted.</p></div><div><h3>Results</h3><p>Twenty-six manuscripts (published between 2014 and 2022) reported on 77 <em>TERT</em> mutated ITN. Sixty-five nodules were malignant (84 %), with 16 (25 %) described with high-risk histopathology, 5 (8 %) described as low-risk, and most without any description. Isolated <em>TERT</em> mutations were malignant in 26/30 ITNs (87 %) with 9 (35 %) described as high risk and none described as low risk. <em>TERT</em> + <em>RAS</em> mutated ITNs were malignant in 29/34 ITNs (85 %) with 3 (10 %) described as high risk and 4 (14 %) described as low risk. Finally, all 5 <em>TERT</em> + <em>BRAF</em>V600E mutated nodules were malignant and 3/5 (60 %) were described as high risk.</p></div><div><h3>Conclusion</h3><p>TERT mutated ITNs have a high risk of malignancy (84 %), and the current data does not show a difference in malignancy rate between isolated <em>TERT</em> mutations and <em>TERT</em> + <em>RAS</em> co-mutated ITNs. When described, <em>TERT</em> + <em>RAS</em> co-mutated ITNs did not have a higher rate of high-risk histopathology as compared to isolated <em>TERT</em> mutated lesions. Most <em>TERT</em> mutated ITNs did not have a description of histopathology risk and the oncologic outcomes, including rate of recurrence, metastases, and disease specific survival, are unknown. Further data is needed to determine if TERT mutated ITNs should be subjected to aggressive initial treatment.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"35 ","pages":"Article 100329"},"PeriodicalIF":3.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623723000170/pdfft?md5=11e066f8c8ab519d2f4a73ae11123795&pid=1-s2.0-S2214623723000170-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138608787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2 inhibitors: Beyond glycemic control","authors":"Irtiza Hasan ,&nbsp;Tasnuva Rashid ,&nbsp;Vishal Jaikaransingh ,&nbsp;Charles Heilig ,&nbsp;Emaad M. Abdel-Rahman ,&nbsp;Alaa S. Awad","doi":"10.1016/j.jcte.2024.100335","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100335","url":null,"abstract":"<div><p>Multiple randomized controlled trials have extensively examined the therapeutic effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors, ushering in a transformative approach to treating individuals with type 2 diabetes mellitus (DM). Notably, emerging reports have drawn attention to the potential positive impacts of SGLT2 inhibitors in nondiabetic patients. In an effort to delve into this phenomenon, a comprehensive systematic literature review spanning PubMed (NLM), Medline (Ovid), and Cochrane Library, covering publications from 2000 to 2024 was undertaken. This systematic review encompassed twenty-six randomized control trials (RCTs) involving 35,317 participants. The findings unveiled a multifaceted role for SGLT2 inhibitors, showcasing their ability to enhance metabolic control and yield cardioprotective effects through a reduction in cardiovascular death (CVD) and hospitalization related to heart failure (HF). Additionally, a renalprotective effect was observed, evidenced by a slowdown in chronic kidney disease (CKD) progression and a decrease in albuminuria. Importantly, these benefits were coupled with an acceptable safety profile. The literature also points to various biological plausibility and underlying mechanistic pathways, offering insights into the association between SGLT2 inhibitors and these positive outcomes in nondiabetic individuals. Current research trends indicate a continual exploration of additional role for SGLT2 inhibitors in. Nevertheless, further research is imperative to fully elucidate the mechanisms and long-term outcomes associated with the nondiabetic use of SGLT2 inhibitors.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"35 ","pages":"Article 100335"},"PeriodicalIF":3.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000061/pdfft?md5=d2676b62a0044b202fed595b731c714f&pid=1-s2.0-S2214623724000061-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140139052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals” [J. JCTE 2 (2015) 55–60]","authors":"Jamie D. Weinand,&nbsp;Joshua D. Safer","doi":"10.1016/j.jcte.2024.100334","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100334","url":null,"abstract":"","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"35 ","pages":"Article 100334"},"PeriodicalIF":3.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221462372400005X/pdfft?md5=54cef2a0104e45157f567e4b90bd9424&pid=1-s2.0-S221462372400005X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140191974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}